反感性寡核酸:神经退行性疾病治疗的有前途的进展
Katarzyna Dudzisz1, Ilona Wandzik2
1Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty of Chemistry, Silesian University of Technology, Krzywoustego 4, 44-100, Gliwice, Poland; Biotechnology Center, Silesian University of Technology, Krzywoustego 8, 44-100, Gliwice, Poland; Joint Doctoral School, Silesian University of Technology, Akademicka 2A, 44-100, Gliwice, Poland.
European journal of pharmacology
|April 26, 2025
概括
反感性寡核酸 (ASOs) 为ALS和SMA等神经退行性疾病提供了有前途的基因疗法. 最近的批准和正在进行的试验突出了ASOs.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 反感性寡核酸 (ASO) 是新兴的针对基因表达的治疗方法.
- 像SMA,ALS和ATTR这样的神经退行性疾病代表了大量未满足的医疗需求.
- 遗传异常是许多神经退行性疾病的关键驱动因素.
研究的目的:
- 审查ASO治疗神经退行性疾病的当前临床环境.
- 突出最近的进展和批准的ASO治疗方法.
- 讨论正在进行的ASO临床试验的潜力和挑战.
主要方法:
- 对ASO疗法的临床试验数据和监管批准的审查.
- 分析ASO机制在调节神经疾病的基因表达.
- 检查针对基因突变的研究,如家族ALS中的SOD1.
主要成果:
- 截至2025年3月,四种基于ASO的疗法已被批准用于SMA,ALS和ATTR.
- 许多ASO正在临床开发中,显示出广泛的治疗潜力.
- 目前正在进行的试验表明,治疗遗传ALS的症状前携带者具有前景.
结论:
- ASO代表了神经退行性疾病的验证和扩展的治疗类.
- 针对特定的遗传缺陷提供了一个强大的疾病修饰策略.
- 进一步的研究和临床研究对于实现ASO的全部潜力至关重要.
相关概念视频
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K


